96483-83-9

Basic information

• Product Name: 3-benzyl-3,8-diazabicyclo[3.2.1]octane-2,4-dione
• Synonyms: 3-benzyl-3,8-diazabicyclo[3.2.1]octane-2,4-dione
• CAS NO: 96483-83-9
• Molecular Weight: 230.266
• Mol File: 96483-83-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 3-benzyl-3,8-diazabicyclo[3.2.1]octane-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 3-benzyl-3,8-diazabicyclo[3.2.1]octane-2,4-dione(96483-83-9)
• EPA Substance Registry System: 3-benzyl-3,8-diazabicyclo[3.2.1]octane-2,4-dione(96483-83-9)

Safety Data

• Hazardous Substances Data: 96483-83-9(Hazardous Substances Data)

Upstream product

• 1384448-78-5 (2R,5S)-ethyl 1-benzyl-5-(benzylcarbamoyl)pyrrolidine-2-carboxylate 
• 429685-63-2 8-allyl-3-benzyl-3,8-diaza-bicyclo[3.2.1]octane-2,4-dione 
• 17783-46-9 3-benzyl-2,4-dioxo-8-methyl-3,8-diazabicyclo-(3.2.1)octane 
• 52321-06-9 cis-1-benzylpyrrolidine-2,5-dicarboxylic acid diethyl ester 
• 54221-37-3 diethyl meso-2,5-dibromoadipate 
• 37061-44-2 3,8-dibenzyl-3,8-diazabicyclo[3.2.1]octane-2,4-dione 

Downstream Products

• 67571-90-8 3-benzyl-3,8-diazabicyclo[3.2.1]octane 
• 93428-54-7 C₁₃H₁₈N₂*ClH 
• 93428-54-7 3-benzyl-3,8-diazabicyclo [3.2.1] octane, dihydrochloride 
• 149771-43-7 3-benzyl-8-(tert-butoxycarbonyl)-3,8-diazabicyclo[3.2.1]-octane 
• 149771-44-8 8-t-butoxycarbonyl-3,8-diazabicyclo[3.2.1]octane 
• 90673-35-1 3,8-diazabicyclo[3.2.1]octane dihydrochloride 

Relevant articles and documents

Pyruvate kinase activators for use in therapy

Described herein are methods for using compounds that activate pyruvate kinase.

Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine

A series of novel N3/8-disubstituted-3,8-diazabicyclo[3.2.1]octanes in order to improve the in vitro activity of the prototype 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridyl-4-yl)methylpiperazine (1) were synthesized and evaluated by assays of growth inhibition against several tumor cell lines. Compounds 2a,b,f and m demonstrated not only growth-inhibitory activities against leukemia cancer cells, but also fairly good activities against the growth of certain solid tumors. Among them, 2a is the most potent one with IC50 values in the low micromolar range. Moreover, compound 2a has been selected for in vitro testing on MCF-7 cell to evaluate the mode of action of this lead compound.

N-benzenesulfonyl l-proline compounds as bradykinin antagonists

This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein X1 and X2 are halo; R1 and R2 are independently hydrogen or C1-4 alkyl; R3 and R4 are each hydrogen or halo; and R5 is (a) —C3-9 diazacycloalkyl optionally substituted with C5-11 azabicycloalkyl; (b) —C3-9 azacycloalkyl-NH—(C5-11 azabicycloalkyl optionally substituted with C1-4 alkyl); (c) —NH—C1-3 alkyl-C(O)—C5-11 diazabicycloalkyl; (d) —NH—C1-3 alkyl-C(O)—NH—C5-11 azabicycloalkyl, the C5-11 azabicycloalkyl being optionally substituted with C1-4 alkyl; (e) —C3-9 azacycloalkyl optionally substituted with C3-9 azacycloalkyl; or (f) —NH—C1-5 alkyl-NH—C(O)—C4-9 cycloalkyl-NH2. These compounds are useful for the treatment of medical conditions mediated by bradykinin such as inflammation, allergic rhinitis, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.